Teva Pharmaceutical Industries Ltd. TEVA announced that its anti-calcitonin gene-related peptide (“CGRP”) injection, Ajovy, was granted marketing approval by the European Commission for prophylaxis of ...

In the rapidly changing landscape of migraine therapeutics, providers are faced with the challenge of navigating unfamiliar waters. Parenteral therapies targeting calcitonin gene-related peptide (CGRP ...

Key opinion leaders discuss the various adverse events of emerging CGRP monoclonal antibody treatments and compare efficacy data. Neil Minkoff, MD: What is your impression of the efficacy across the 4 ...

Six different injected or oral medicines that target the protein CGRP should be among the first drugs people try to prevent migraine, the American Headache Society advises. People with migraine should ...

Eli Lilly’s CGRP migraine prevention drug Emgality is in a heated market share race with Amgen’s Aimovig and Teva’s Ajovy, but in the second quarter, it gained some steam. By the end of the period, ...

Amgen had a head start with its first-to-market CGRP launch Aimovig, but its rivals are giving the company some fierce competition. As of the week ended Aug. 23, Aimovig now holds less than half of ...

Calcitonin gene-related peptide (CGRP) inhibitors -- a group of drugs commonly used to treat migraine -- were associated with decreased rates of acne and rosacea compared with drugs that did not ...

Most patients with migraine are women, and this observation is reflected in clinical studies. A pharmacologist and a neurologist from the United States argue that the efficacy of calcitonin ...

As estrogen levels fluctuate, a new study has found for female participants with migraine, their levels of the protein calcitonin gene-related peptide (CGRP) that plays a key role in starting the ...

Alder BioPharma has reported new data from its phase 3 trial of CGRP inhibitor eptinezumab in episodic migraine, adding to evidence backing the drug as it prepares for what looks set to be a fierce ...